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feedback on a 4 point scale for applicability, comprehensibility and appropriateness 
of the response options of each item. They were also encouraged to leave free-text 
feedback. Results: A total of 218 subjects provided feedback, 61.47% female. Mean 
age was 55.78 years, with patients from 18-80 years, 40.37% between 55-65 years. 
The most represented conditions were Parkinson’s (27), Fibromyalgia (23), Multiple 
Sclerosis (20) and Rheumatoid Arthritis (19). The mean number of quantitative 
assessments per item was 55.74, while the mean number of comments was 11.64. 
Considering a cut-off of 2 points in the 0-3 scale, 18 items had low applicability, 
just one item had low comprehensibility and all items had appropriate response 
options. ConClusions: An impressive amount of feedback was obtained in just 
a week using the Open Research Exchange platform. The lowest scores were in 
applicability. However, as the items are destined to an adaptive test, some of them 
are very extreme (destined to severe cases). Therefore applicability was considered 
a secondary concern. With this caveat, quantitative feedback was very positive, and 
added to the great amount and detail of qualitative feedback suggest some changes 
that we think will greatly improve the instrument.
PRM176
Quality of life in Patients undeRgoing HeModialysis: a Vision of tHe 
influence of tiMe
Maia R.C.F.1, Monteiro W.M.S.1, Silva M.G.C.2, Almeida R.F.C.1
1Secretaria de Saúde do Estado do Ceará, FORTALEZA, Brazil, 2UECE, Fortaleza, Brazil
objeCtives: To measure and compare the quality of life in patients undergoing 
hemodialysis with respect to time. Methods: An observational, prospective study 
conducted in 2012/2013 consisting of 50 patients with Terminal Chronic Kidney 
Disease, undergoing HD in a public clinical care within the metropolitan area of 
Fortaleza. We used the KDQOL instrument early in therapy and one year after its 
beginning in order to observe changes in quality of life over time. Statistical analy-
sis included frequency distribution and measures of central tendency. Results: 
The general dimensions of this instrument indicate that the dimensions “physical 
function”, “social function” and “emotional function” had the lowest scores early 
in therapy. It is observed that these same dimensions showed significant improve-
ments in patients after one year of HD. Only “general health” was not significant. 
At baseline, specific dimensions of the instrument as “professional role”, “sexual 
function” and “disease overload” have the lowest scores and remain the same after 
one year of the begin of therapy, showing that the time difference has no statistical 
significance. ConClusions: The quality of life of patients undergoing hemodialysis 
after a year of therapy is superior to the quality of life showed at the beginning of 
treatment although this difference is not statistically significant. It is important 
to search for alternatives that can positively influence the quality of life of these 
patients.
PRM177
MetHods used to MeasuRe Patient PRefeRences in PsoRiasis 
tReatMents – an oVeRView witH RegaRds to tHe geRMan iQwig  
and g-Ba
Gutknecht M., Herrlein O., Augustin M.
University Medical Center Hamburg-Eppendorf, Hamburg, Germany
objeCtives: According to the methodology of the German Institute for Quality 
and Efficiency in Healthcare (IQWiG), the benefit assessment of a new treatment 
intervention refers to patient-reported outcomes exclusively. Given the existence of 
different patient-relevant outcomes the Federal Joint Committee (G-BA) can engage 
the IQWiG to aggregate these to one comprehensive benefit measurement. So far, 
the IQWiG uses no standardized method for this. In its current method paper, among 
the benefit QALY, the IQWiG refers to methods of multi-criteria decision making 
or preference evaluation like analytic hierarchy process and conjoint analysis. For 
psoriasis, one of the most frequent chronic skin diseases worldwide, a variety of 
treatment interventions is available. In the light of recent discussions, the objective 
was to give an overview of methods which have been used to date to prioritize and 
weight patient-relevant outcomes in psoriasis treatment. Methods: The present 
review is based on a systematic literature research until 31 December 2013 in the 
databases PubMed, Embase, Ovid Medliner, Cochrane Library, EconLit and CINAHL 
using the keywords “psoriasis” and “preferences”. Results: The search resulted in 
288 hits without duplicates. 16 articles met the predefined inclusion criteria. In addi-
tion to methods to calculate QALY like time-trade off and standard gamble, conjoint 
analysis, willingness-to-pay and other preference methods were used. In view of the 
method paper of IQWiG, no study exists in the field of psoriasis where the analytic 
hierarchy process was used. ConClusions: The results of the presented review 
show, that the analytic hierarchy process was not used in psoriasis studies, so far. 
The use of this method in future studies might provide new essential knowledge 
in the evaluation of patient preferences in psoriasis treatment.
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Hansen L.1, Vestergaard P.1, Petersen K.D.2
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objeCtives: The QUALIOST (quality in life questionnaire in osteoporosis) is one of 
the most commonly used osteoporosis-specific health-related quality of life (HRQoL) 
questionnaires and it is often used in clinical studies to document the longitudinal 
impact of osteoporosis and related fractures. It is unknown whether the QUALIOST is 
better at estimating HRQoL for osteoporotic fracture patients compared to the com-
monly used EQ-5D questionnaire. Preference scores have not yet been developed for 
the QUALIOST and, thus, cost-utility analyses are difficult to perform. The purpose of 
the present paper is to describe the first steps of a future study on mapping from the 
QUALIOST to the EQ-5D questionnaire. Methods: A questionnaire, containing both 
EQ-5D-5L and QUALIOST, is distributed to patients in an orthopaedic outpatient clinic 
in Denmark and the aim is to include 150 patients. Patients above 50 years of age and 
with a recent fracture (less than 2 weeks old) are invited to participate in the study. 
effects associated with EQ-5D-5L, this measure is still not a key requirement for cost-
effectiveness modeling in selected HTA submissions. ConClusions: EQ-5D-3L has 
the potential to distort the true cost-effectiveness in conditions that are insensi-
tive to the measure. Awareness and requirements for the use of EQ-5D-5L should 
increase amongst manufacturers and HTA bodies to ensure submissions present 
accurate cost-effectiveness models. Further research into the evaluation of cost-
effectiveness results between these two measures following the introduction of 
validated independent value sets for EQ-5D-5L is encouraged.
PRM173
Modification of Patient RePoRted outcoMes MeasuRes of 
coMPliance, gastRointestinal syMPtoMs, PalataBility and 
tReatMent satisfaction foR Patients needing iRon  
cHelation tHeRaPy
Lasch K.1, Côté I.2, Roma T.2, Srivastava B.2, Horodniceanu E.G.3, Dhatt H.3, Carter J.A.3, Bal V.2
1Pharmerit International, Cambridge, NJ, USA, 2Novartis Pharmaceuticals Corporation, East 
Hanover, NJ, USA, 3Pharmerit International, Bethesda, MD, USA
objeCtives: In patients requiring frequent blood transfusions due to transfusion 
dependent anemia (TDA) (e.g., sickle cell disease [SCD]) and myelodysplastic syn-
drome (MDS), life expectancy is directly related to the quality of chelation therapy, 
and poor adherence to treatment increases the risk of complications and shortens 
survival1. Improved palatability ratings and gastrointestinal (GI) tolerability could 
have positive impacts on adherence with iron chelation therapy (ICT) 2. Therefore, 
patient-reported outcomes (PROs) measuring compliance, GI symptoms, and pal-
atability were developed and the Satisfaction with Iron Chelation Therapy (SICT) 
questionnaire was modified, as electronic PROs (ePROs) specific to a new formula-
tion of ICT. Methods: Eleven patients with TDA or MDS provided informed con-
sent and were included in this qualitative study. Two sets of face-to-face cognitive 
interviews were conducted iteratively; modifications to items were debriefed in the 
second set. Interviews began open-endedly to elicit patients’ spontaneous experi-
ences with ICT. Interviews were audio recorded and transcribed. An item tracking 
matrix documented the changes made for each item. Data analysis used ATLAS. ti 
software. This study was conducted according to best practices for development3 
and modification4 of PROs in an ePRO format. Results: Patients were 73% (n= 8) 
male and 27% (n= 3) female with a mean age of 43 (range 14-81 years); 45% (n= 5) had 
SCD, and 27% (n= 3) had MDS. Patient spontaneous reports and cognitive debriefing 
responses confirmed concepts in the draft PROs and helped eliminate irrelevant 
items. Changes made after cognitive debriefing ensured the comprehensibility, lack 
of redundancy, and appropriate instructions and response options. The resultant 
PROs included the Compliance (2 items), GI Symptom Diary (6 items), Palatability (4 
items), and modified SICT (13 items). ConClusions: Results support the content 
validity of PRO measures of compliance, GI symptoms, palatability, and satisfaction 
with ICT. These measures require psychometric validation of validity, reliability, and 
responsiveness before recommending their use in future clinical research.
PRM174
tHe iMPoRtance of MigRation assessMents: ecoa tRanslations and 
linguistic Validation
Sweeney E., Kelley T.
TransPerfect, New York, NY, USA
objeCtives: As the use of clinical outcomes assessments (COAs) in global studies 
continues to increase, early collaboration between eCOA and linguistic validation 
providers becomes critical to the success of global initiatives. Early involvement 
of a linguistic validation partner in the eCOA migration process offers insight into 
migration issues that may not be present in the English version of the instrument, 
but if not identified, can lead to study delays as well as increased costs for the spon-
sor. Methods: An examination was conducted of previous linguistic validation 
projects that included either newly developed eCOA instruments or pen/paper to 
eCOA migration. A comparison of various eCOA platforms, the corresponding issues, 
and details relating to migration solutions were assessed. Results: Frequently, a 
line of text that is present in an eCOA platform (proprietary software, Excel, etc.) 
is coded such that it populates into the eCOA device in multiple locations. These 
segments are sometimes referred to as “computed text” and are commonly used 
for response options that repeat for multiple items of a questionnaire. While this 
may work adequately in English, many languages require a variance in the transla-
tion used based on the context of the item and/or response choice. While a pen/
paper version may allow for these variances, the initial eCOA programming may 
not. The variance is only determined further into the linguistic validation process 
and presents challenges if the device requires re-programming. ConClusions: A 
migration assessment, separate from equivalency testing, allows for the eCOA and 
linguistic validation providers to assess the initial setup of the eCOA software. This 
assessment can determine whether system modifications are necessary to allow 
for the translations to properly be mapped and displayed. This additional step will 
also prevent study delays as well as quality issues as it allows issues to be addressed 
early and avoid later difficulties.
PRM175
Patient dRiVen QuestionnaiRe deVeloPMent, iteM feedBack fRoM 
useRs of a Patient netwoRk
Castejón N.1, Harrington M.2, Campillo-Álvarez Á.1, Rebollo P.1
1LASER ANALYTICA, Oviedo, Spain, 2PatientsLikeMe, Cambridge, MA, USA
objeCtives: CAT-Health is a generic health related quality of life computer adaptive 
test developed and validated in Spain. Based on its 96 item pool, a new instrument 
is being developed in English. The objective of the present study was to obtain 
substantial feedback from patients on the items, through Open Research Exchange 
platform, that centralizes PROM research and is integrated with PatientsLikeMe, 
an online community. Methods: The item pool was split in four sets of 24 items 
each. 750 patients with various conditions received an e-mail that included link 
to a survey open for 7 days. They were asked to answer one of the sets and give 
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two back translations of the English ItchRO. Cognitive interviews with five children 
with ALGS (patient report) and five parents (observer report) were to be performed. 
Key inclusion criteria were: children aged 5-9 years with cholestatic liver disease 
(ALGS) or progressive familial intrahepatic cholestasis (PFIC), who were also expe-
riencing itching. Results: Recruitment was challenging and threatened to delay 
the clinical trial programme. Thus, recruitment was extended to include children 
who were 3-17 years of age, and in Spain and Germany, patients with alternative 
pathologies that manifested primarily with generalized pruritus were included. The 
final sample included: 15 with ALGS (France n= 5; Poland n= 5; Germany n= 3; Spain 
n= 2), 2 with PFIC (Spain), 2 with atopic dermatitis (Germany) and 1 with contact 
dermatitis (Spain). The ItchRO translations were well understood; there were no 
apparent differences in translation interpretations by disease state. ConClusions: 
Recruitment in linguistic validation projects in rare diseases can be a hurdle, yet 
patient understanding, rather than those of ‘lay people, ’ is preferable in paediatrics 
to ensure adequate interpretation, which can vary substantially across children. As a 
result patients with similar symptom and impact characteristics could be recruited 
if recruiting the primary population is likely to delay clinical trial research in rare 
diseases, where there is an urgent need for treatment.
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ResPonsiVeness and MiniMal clinically iMPoRtant diffeRence of a 
sPecific HealtH Related Quality of life (HRQol) QuestionnaiRe foR 
HoMe enteRal nutRition (Hen) Patients: nutRiQol® QuestionnaiRe
Cuerda C.1, Virgili N.2, Irles J.A.3, Cuesta F.4, Apezetxea A.5, Casanueva F.6, Carrillo L.7,  
Layola M.8, Lizán L.9
1Hospital Universitario Gregorio Marañón, Madrid, Spain, 2Hospital Bellvitge, Barcelona, Spain, 
3Hospital Universitario Nuestra Señora de Valme, Sevilla, Spain, 4Hospital San Carlos, Madrid, 
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objeCtives: To determine NutriQoL® responsiveness and minimal clinically impor-
tant difference (MCID) in patients receiving HEN. Methods: NutriQoL®, a specific 
questionnaire, developed and validated in Spain, for the assessment of HRQoL in 
patients receiving HEN regardless of the underlying condition was administered 
to a prospective cohort from 4 Spanish hospitals. It includes 17 pairs of items of 
HEN-related HRQoL, scoring from -51 (worst HRQoL) to 51 (best HRQoL). NutriQoL® 
was completed three times within 1-month (±15 days) intervals (visit 1/visit 2/visit 
3). Responsiveness was assessed by estimating the effect size and the standard-
ized response mean between visits 1 and 3. For MCID calculation an anchor-based 
approach was performed. Interquartile range of the change in NutriQoL® from 
patients, who reported changes in their health-status (worse or better) between 
visits 2 and 3, was used. Results: A total of 86 subjects who presented clinical 
changes between visits [63% male; mean (SD) age 61 (13)] participated. Cancer was 
the main diagnosis leading to HEN prescription (66.3%). NutriQoL® scores were 16.98 
(14.57), 16.63 (14.86) and 18.92 (15.25) for visit 1, 2 and 3, respectively. Up to 78.79% of 
patients reported improvements in their HRQoL since the introduction of HEN. The 
estimated effect size and the standardized mean response between visit 1 and 3 
were 0.23 and 0.24. Regarding MCID, NutriQoL® total scores difference between visit 
2 and 3 in those patients that perceived changes in their health status was between 
-3.75 and 4.25 (interquartile range). ConClusions: NutriQoL® responsiveness is 
moderate. This may be due to the limited temporal period between visits since most 
of patients referred improvements in their condition. A difference of ±4 points on 
NutriQoL® total score regarding a previous administration demonstrates a clinical 
change that affects patients HRQoL.
PRM183
MeasuRing cHange in Quality of life: can we distinguisH Recall Bias 
and scale RecaliBRation?
Blome C., Augustin M.
University Medical Center Hamburg-Eppendorf, Hamburg, Germany
objeCtives: Treatment effects on health-related quality of life (QoL) often differ 
depending on whether they are measured prospectively (before and after treatment) 
or retrospectively (after treatment only). It is not clear which of either evaluations is 
more valid: Prospective evaluations may be biased by scale recalibration (a changed 
understanding of the response scale), and retrospective evaluations may be biased 
by recall bias (a wrong assessment of former QoL). Methods: Based on an analy-
sis of literature, we present an overview on (a) possible biases in prospective and 
retrospective measurement of QoL, (b) how these biases are named and defined in 
literature, and (c) current approaches to distinguish scale recalibration and recall 
bias. Results: The definitions of different biases are inconsistent. Many authors 
do not clearly distinguish measurement bias from true change. Furthermore, some 
consider only scale recalibration or only recall bias. There are different approaches 
for distinguishing scale recalibration and recall bias. We argue that these make too 
extensive assumptions to be valid. ConClusions: Much of the current discussion 
on the validity of prospective and retrospective QoL measurement suffers from 
unclear definitions, especially of “response shift” and “recall bias”, or from neglect-
ing one of the possible biases. We suggest more elaborate definitions for different 
types of bias, and recommend taking both kinds of bias into consideration when 
measuring change in QoL. Due to a lack of valid methods, there is not enough evi-
dence on the extent of these biases yet; therefore the best approach for outcomes 
studies might be to include both prospective and retrospective assessments. In the 
long run, valid methods need to be developed to determine the most valid method 
of QoL assessment.
PRM184
MetHods to elicit Patient PRefeRences: a case study in Metastatic 
BReast canceR
Copher R.1, DiBonaventura M.2, Basurto E.2, Faria C.1, Lorenzo R.2
1Eisai, Inc., Woodcliff Lake, NJ, USA, 2Kantar Health, New York, NY, USA
The patients are asked to complete the questionnaire at initial contact with the out-
patient clinic and at four follow-up time points; one week, and one, three, and twelve 
months post-fracture). The last inclusion date will be December 31st2014. Results: 
The hypothesis is that the QUALIOST will provide a better estimate of the impact 
of osteoporosis-related fractures on HRQoL as it contains disease-relevant aspects, 
which may not be sufficiently covered in the generic EQ-5D-5L questionnaire. We will 
develop a mapping algorithm to predict EQ-5D derived utilities for Danish fracture 
patients from the QUALIOST, which can be used in future studies, where utilities then 
may be estimated from QUALIOST results. ConClusions: Mapping from QUALIOST 
scores to EQ-5D-5L derived utilities will enable estimation of preference-based HRQoL 
utilities for patients with osteoporotic fractures.
PRM179
ReView of Patient-RePoRted outcoMes in diaBetic MaculaR edeMa
Ishii K., Narimatsu A., Adachi K.
Bayer Yakuhin, Ltd., Tokyo, Japan
objeCtives: Diabetic macular edema (DME) is a serious condition occurring in 
patients with diabetic retinopathy (DR) which is a common complication of diabetes. 
Understanding not only objective measurements such as visual acuity, but also the 
patients’ perspective is important in gaining a comprehensive understanding of 
the impact of DME and its treatment on their functioning and well-being. The aim 
of this study is to understand possible measurements to investigate the impact of 
DME on health-related quality of life (HRQoL), by identifying currently available 
measurements, their ability to differentiate between DR and DME, and possible 
reasons for difficulties in measuring HRQoL specifically for DME. Methods: We 
performed a literature review on articles describing instruments of patient-reported 
outcomes (PRO) for DME. We summarized the current evidence on the usefulness of 
the instruments and whether they differentiate between DR and DME. In addition, 
we investigated possible hurdles in measuring HRQoL for DME, given the clinical 
understandings of the systemic aspects of DME. Results: We identified seven con-
dition-specific or vision-specific measurements and seven general measurements 
including generic HRQoL and utilities for possible instruments for DME. However, 
realistic use for DME appears questionable even for vision-related measurements. 
The possible reasons could be that: 1) DME is not the primary disease, 2) many of 
DME patients have comorbidities such as DR, cataracts, and DR-induced glaucoma, 
and 3) those comorbidities itself may lead to decreased visual acuity with decreased 
HRQoL. ConClusions: Evidence is limited when measuring the impacts of DME 
on diabetic patients largely due to the lack of an effective PRO instrument for DME. 
The major difficulties in developing such instruments is that DME patients have 
complex health statuses, which provides for multiple reasons in decrease of QoL 
which may not be directly due to their DME.
PRM180
deVeloPMent of tHe BeHaVioR Rating inVentoRy of executiVe 
function - PRescHool VeRsion (BRief-P) in 10 languages
Vasarri S.1, Isquith P.K.2
1Mapi, Lyon, France, 2Dartmouth University, Norwich, VT, USA
objeCtives: The Behavior Rating Inventory of Executive Function Preschool Version 
(BRIEF-P) was designed to provide a better understanding of preschool children’s self-
control and problem-solving skills. It is composed of 63 items organized in five clinical 
scales which measure five aspects of executive functioning (Inhibit, Shift, Emotional 
Control, Working Memory, Plan/Organize). It is used to evaluate children aged 2-5 years 
old with a wide spectrum of developmental and acquired neurological conditions, such 
as learning disabilities, Tourette’s disorder, traumatic brain injury, attention-deficit/
hyperactivity disorder or pervasive developmental disorders/autism. The objective of 
this study was to develop the BRIEF-P in 10 languages (Afrikaans, Bulgarian, Estonian, 
Greek, Japanese, Lithuanian, Romanian, Serbian, Slovak, Ukrainian). Methods: The 
following methodology was used: (1) Clarification of concepts with the developers; (2) 
Forward and backward translation steps in each target country. Results: The transla-
tion process did not reveal any cultural issues since most of the concepts assessed 
were cross-culturally relevant. The main difficulties consisted in finding conceptual 
equivalents of the original items with strong idiomatic content or containing words 
pertaining to the same semantic field. For instance, the most problematic items were 
items 10, 23 and 50. Item 23 (Is fidgety, restless, or squirmy) raised difficulties since it was 
not always possible to find direct equivalents for all adjectives in all languages. As 
for item 50 [Acts overwhelmed or overstimulated in crowded, busy situations (such as lots of 
noise, activity, or people)], discussions focused on how to convey the differences between 
“overwhelmed” and “overstimulated”, as well as between “busy” and “crowded.” 
In all cases, issues were solved with repeated discussions with the develop-
ers. ConClusions: The cross-cultural adaptation of the BRIEF-P into 10 languages 
required an international collaboration. The involvement of the developers during 
the whole process enabled the production of conceptually equivalent and culturally 
appropriate measures.
PRM181
cHallenges in RecRuiting Patients foR tHe linguistic Validation of 
PRo instRuMents deVeloPed foR RaRe diseases: a case study witH 
alagille syndRoMe
Kennedy C.1, Abetz-Webb L.2, Lambe J.3
1Lumena, San Diego, CA, USA, 2Patient-Centred Outcomes Assessments LTD, Macclesfield, 
Cheshire, UK, 3Mapi, Lyon, France
objeCtives: Observer and Patient Itch-reported Outcome Instruments (ItchRO) 
are electronic morning and evening diaries developed in US English to assess itch-
related symptom severity (rubbing, scratching, skin damage, sleep disturbances or 
irritability) in pediatric patients suffering from rare cholestatic liver diseases such 
as Alagille Syndrome (ALGS). Itching is a key symptom in ALGS and significantly 
impacts on a child’s daily life. This research presents the recruitment challenges 
faced during the linguistic validation of the ItchRO into French, German, Polish and 
Spanish in ALGS patients. Methods: Native translators performed two forward and 
